Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | CASR | P41180 | 1/20 | 0.36 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1847342 | 0.87 | L3MBTL1 (0.43) | L3MBTL1SMN1; SMN2MAPK1ALDH1A1LMNA | |
| SCHEMBL28880344 | 0.86 | L3MBTL1 (0.35) | L3MBTL1SMN1; SMN2MAPK1ALDH1A1LMNA | |
| SCHEMBL28880345 | 0.86 | L3MBTL1 (0.35) | L3MBTL1SMN1; SMN2MAPK1ALDH1A1LMNA | |
| SCHEMBL28880523 | 0.84 | SOS1 (0.35) | L3MBTL1SMN1; SMN2MAPK1ALDH1A1LMNA | |
| SCHEMBL28880525 | 0.84 | SOS1 (0.35) | L3MBTL1SMN1; SMN2MAPK1ALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL27776753 | 0.83 | L3MBTL1 (0.38) | L3MBTL1SMN1; SMN2MAPK1ALDH1A1LMNA | |
| SCHEMBL8595323 | 0.81 | TSHR (0.49) | L3MBTL1SMN1; SMN2MAPK1ALDH1A1LMNA | |
| SCHEMBL27621058 | 0.80 | KDM4E (0.44) | SMN1; SMN2MAPK1ALDH1A1LMNAGAA | |
| SCHEMBL6684454 | 0.80 | MAPK1 (0.41) | L3MBTL1SMN1; SMN2MAPK1ALDH1A1LMNA | |
| SCHEMBL15559998 | 0.78 | CXCL8 (0.44) | L3MBTL1SMN1; SMN2MAPK1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023210623-A1 | HALOALKYL SULFONE ANILIDE COMPOUND AND HERBICIDE CONTAINING SAME | 株式会社エス・ディー・エス バイオテック | 2023-11-02 | — | — | WO | disclosed |
| CN-114380718-B | Acylation method of aniline compound | 河南农业大学 | 2022-09-30 | — | — | CN | disclosed |
| CN-114380718-A | Acylation method of aniline compound | 河南农业大学 | 2022-04-22 | — | — | CN | disclosed |
| WO-2014184070-A1 | MIXTURES OF HALOALKYLSULFONANILIDE DERIVATIVES AND HERBICIDES | SYNGENTA LIMITED (GB) | 2014-11-20 | — | — | WO | disclosed |
| WO-2014184071-A1 | MIXTURES OF HALOALKYLSULFONANILIDE DERIVATIVES AND HERBICIDES | SYNGENTA LIMITED (GB) | 2014-11-20 | — | — | WO | disclosed |
| EP-2420493-A1 | HALOALKYLSULFONANILIDE DERIVATIVE | Nissan Chemical Industries, Ltd. (JP) | 2012-02-22 | — | — | EP | disclosed |
| US-20120029187-A1 | HALOALKYLSULFONANILIDE DERIVATIVE | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-02-02 | — | — | US | disclosed |
| EP-2336104-A1 | ORTHO-SUBSTITUTED HALOALKYLSULFONANILIDE DERIVATIVE AND HERBICIDE | Nissan Chemical Industries, Ltd. (JP) | 2011-06-22 | — | — | EP | disclosed |
| EP-1030846-B1 | METHOD FOR PRODUCING AR(ALK)YLURACILES, NOVEL CORRESPONDING INTERMEDIATE PRODUCTS AND METHOD FOR PRODUCING SAID INTERMEDIATE PRODUCTS | BAYER CROPSCIENCE AG (DE) | 2003-07-16 | — | — | EP | disclosed |
| US-6476224-B2 | N-(4-CYANO-2,5- DIFLUORO-PHENYL) -3-(DIMETHYLAMINOCARBONYLAMINO)-4,4,4-TRIFLUORO-2-BUTENAMIDE AND 1,2-DIMETHOXYETHANE ARE HEATED TO FORM AR(ALK)YL URACIL COMPOUND | BAYER AKTIENGESELLSCHAFT (DE) | 2002-11-05 | — | — | US | disclosed |
| US-20020022727-A1 | Method for producing ar(alk)yluraciles, novel corresponding intermediate products and method for producing said intermediate products | GALLENKAMP BERND (DE) | 2002-02-21 | — | — | US | disclosed |
| US-6262291-B1 | CHEMICAL INTERMEDIATE FOR HERBICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2001-07-17 | — | — | US | disclosed |
| US-6225470-B1 | HEATING SUBSTITUTED AMINOALKENAMIDES IN PRESENCE OF DILUENTS TO PRODUCE AR(ALK)YLURACIL | BAYER AKTIENGESELLSCHAFT (DE) | 2001-05-01 | — | — | US | disclosed |
| US-6169182-B1 | REACTING SUBSTITUTED N-(CYANOPHENYL)AMINOALKENAMIDES WITH CARBONIC ACID DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2001-01-02 | — | — | US | disclosed |
| EP-1030846-A1 | METHOD FOR PRODUCING AR(ALK)YLURACILES, NOVEL CORRESPONDING INTERMEDIATE PRODUCTS AND METHOD FOR PRODUCING SAID INTERMEDIATE PRODUCTS | BAYER AG (DE) | 2000-08-30 | — | — | EP | disclosed |
| WO-1999025698-A1 | METHOD FOR PRODUCING AR(ALK)YLURACILES, NOVEL CORRESPONDING INTERMEDIATE PRODUCTS AND METHOD FOR PRODUCING SAID INTERMEDIATE PRODUCTS | BAYER AKTIENGESELLSCHAFT (DE) | 1999-05-27 | — | — | WO | disclosed |
| EP-0880506-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED CYANOPHENYL URACILS FROM SUBSTITUTED AMINOALKENE ACID CYANOPHENYL AMIDES | BAYER AG (DE) | 1998-12-02 | — | — | EP | disclosed |
| WO-1997029094-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED CYANOPHENYL URACILS FROM SUBSTITUTED AMINOALKENE ACID CYANOPHENYL AMIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1997-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029187-A1 | HALOALKYLSULFONANILIDE DERIVATIVE | CBR3, CBR1, HDHD5 | L3MBTL1 118/4885SMN1; SMN2 4115/4885MAPK1 1508/4885 |
| US-20020022727-A1 | Method for producing ar(alk)yluraciles, novel corresponding intermediate products and method for producing said intermediate products | ALK, ALKBH5, ALKBH1 | L3MBTL1 2805/4885SMN1; SMN2 3219/4885MAPK1 2792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.